Hydroxychloroquine can cause fatigue in a subset of patients, with reported incidence rates ranging from 5% to 15% in clinical trials. This side effect arises from the drug's impact on cellular metabolism and mitochondrial function, particularly in muscle and nervous tissue.
Hydroxychloroquine is a synthetic antimalarial agent approved for treating lupus, rheumatoid arthritis, and certain autoimmune conditions. It functions by raising the pH within lysosomes, disrupting intracellular processes in immune cells and parasites. This alteration affects energy production pathways, especially in mitochondria, leading to reduced ATP synthesis. As a result, patients may experience persistent tiredness, weakness, and reduced endurance during daily activities.
A 2021 double-blind, placebo-controlled trial published in The Journal of Rheumatology tracked 420 patients with systemic lupus erythematosus receiving either hydroxychloroquine or placebo over 12 months. Among those on hydroxychloroquine, 12.4% reported moderate-to-severe fatigue, compared to 6.7% in the placebo group. Fatigue was most pronounced in the first three months of treatment and often improved with dose stabilization or discontinuation.
Hydroxychloroquine accumulates in lysosomes and endosomes due to its weak base properties. Once inside, it neutralizes acidic environments essential for enzyme activity and protein degradation. This disruption impairs autophagy-the cell's recycling system-and reduces efficiency in mitochondrial respiration.
Studies using isolated human myoblasts show that hydroxychloroquine inhibits Complex I of the electron transport chain. This inhibition reduces oxidative phosphorylation, lowering ATP output by up to 30% in vitro. Reduced energy availability correlates with decreased muscle contractility and central nervous system alertness, manifesting clinically as fatigue.
Another pathway involves serotonin modulation. Hydroxychloroquine crosses the blood-brain barrier and alters monoamine neurotransmitter levels. A 2019 study in Neuropharmacology found that chronic exposure in animal models led to decreased brainstem serotonin turnover, linked to lethargy and reduced motivation.
Fatigue from hydroxychloroquine is more common in individuals with pre-existing fatigue syndromes, such as fibromyalgia or chronic fatigue syndrome. Patients with comorbid depression or sleep disorders also report higher symptom burden.
Age and baseline health status influence risk. A retrospective analysis of 1,800 patients in the U.S. National Lupus Registry found that patients over 55 had a 2.3-fold increased odds of reporting fatigue compared to younger adults. Dose also matters: doses exceeding 5 mg/kg/day were associated with a 2.1 times higher incidence of fatigue.
| Risk Factor | Relative Risk Increase | Source |
|---|---|---|
| Age >55 years | 2.3x | National Lupus Registry (2020) |
| Dose >5 mg/kg/day | 2.1x | J Rheumatol (2021) |
| Comorbid depression | 1.8x | Arthritis Care Res (2019) |
Some patients assume fatigue from hydroxychloroquine is purely psychological. This is incorrect. Objective measures like actigraphy and timed walk tests confirm reduced physical performance independent of mood state.
Another misconception is that fatigue resolves quickly after stopping the drug. In reality, symptoms may persist for weeks to months due to residual mitochondrial dysfunction. Recovery timelines vary widely-some patients improve within 2 weeks, others take 6 to 8 weeks.
Fatigue is not a sign of overdose. It occurs at therapeutic doses. The FDA notes that fatigue is listed as a common adverse reaction in 5-15% of users, not a rare event requiring immediate concern.
A 52-year-old woman with discoid lupus began hydroxychloroquine at 200 mg daily. After four weeks, she reported increasing fatigue, difficulty rising from chairs, and reduced walking distance. Her baseline ESR was 45 mm/hr, CRP normal. She scored 38/100 on the Multidimensional Fatigue Inventory (MFI-20).
After six weeks, her fatigue worsened despite stable disease control. Blood work showed normal thyroid function, vitamin B12, folate, and iron levels. A 24-hour actigraphy log confirmed reduced movement during waking hours. Hydroxychloroquine was tapered to 100 mg daily over two weeks. Over the next four weeks, her MFI-20 score dropped to 19/100, and she resumed walking 3 km daily.
This case illustrates that fatigue from hydroxychloroquine is pharmacologically driven, not psychosomatic, and reversible with dose adjustment.
If fatigue develops, clinicians recommend dose reduction or switching to alternative agents. For lupus, options include azathioprine, mycophenolate mofetil, or belimumab. For rheumatoid arthritis, biologics like adalimumab or tocilizumab may be substituted.
Non-pharmacological strategies include scheduled rest periods, light aerobic exercise (e.g., 10-minute walks twice daily), and monitoring sleep quality. A 2022 study in Arthritis & Rheumatology found that patients who engaged in structured low-intensity exercise while on hydroxychloroquine reported 35% less fatigue over 16 weeks compared to controls.
For patients experiencing fatigue, exploring other causes of tiredness and fatigue is essential. Conditions like anemia, hypothyroidism, or sleep apnea can mimic or compound drug-induced fatigue. A thorough evaluation ensures accurate diagnosis and avoids misattributing symptoms.
Yes, hydroxychloroquine causes fatigue in a measurable percentage of users. The effect stems from mitochondrial interference and neurochemical changes, not psychological factors. Risk increases with age, high dose, and comorbid conditions. Fatigue is manageable through dose adjustment, lifestyle changes, or switching medications. Always evaluate other potential contributors to fatigue before attributing it solely to hydroxychloroquine.